科伦药业子公司TROP2 ADC芦康沙妥珠单抗联合免疫疗法帕博利珠单抗一线治疗PD-L1阳性局部晚期或转移性非小细胞肺癌获突破性疗法认定

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai Biopharmaceutical Co., has received breakthrough therapy designation from the National Medical Products Administration of China for its ADC drug targeting TROP2 in combination with Merck's PD-1 monoclonal antibody for treating specific types of non-small cell lung cancer (NSCLC) [1] Group 1 - Kelong Pharmaceutical announced that its subsidiary Kelong Botai's ADC drug, Lukanosatuzumab, has been granted breakthrough therapy designation for first-line treatment of PD-L1 tumor proportion score (TPS) ≥ 1% in EGFR gene mutation-negative and ALK-negative locally advanced or metastatic NSCLC [1] - The company also reported that its ADC drug SKB105 (also known as CR-003), targeting integrin β6, has received approval for clinical trials from the National Medical Products Administration for the treatment of advanced solid tumors [1]